Home > Boards > US Listed > Biotechs > vTv Therapeutics (VTVT)

No one, but Ron Perelman, seems exited about

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Investor2014 Member Profile
 
Followed By 18
Posts 6,797
Boards Moderated 0
Alias Born 11/23/16
160x600 placeholder
vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diab... Business Wire - 6/6/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/16/2019 9:11:17 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/16/2019 7:55:26 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/16/2019 7:53:19 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/1/2019 4:51:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/1/2019 4:51:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/1/2019 4:51:29 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 4:45:26 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2019 4:44:43 PM
vTv Therapeutics Announces 2019 First Quarter Financial Results and Update Business Wire - 5/1/2019 4:30:00 PM
vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases Business Wire - 3/28/2019 4:30:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 3/20/2019 8:59:11 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/20/2019 6:05:40 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/19/2019 5:44:08 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/19/2019 5:30:49 PM
vTv Therapeutics Announces $15 Million of Class A Common Stock Financings Business Wire - 3/18/2019 9:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/15/2019 8:05:29 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/15/2019 8:02:24 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2019 4:32:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2019 4:08:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2019 4:08:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/11/2019 4:08:19 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/28/2019 5:58:20 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 2/28/2019 4:15:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/28/2019 4:14:43 PM
Investor2014   Saturday, 03/30/19 10:11:02 AM
Re: None
Post # of 441 
No one, but Ron Perelman, seems exited about the posthoc subgroup study of 15 diabetes type 2 patients and the prospect of approval for Azeliragon.

What happened, are retail investors no longer duped by Perelman’s purchases?

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist